Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2, page-52

Please refer to the attached ASX announcement:
ATL1102 License Agreement with Teva Pharmaceutical Industries Ltd. Dated 24-March 2010
http://www.aspecthuntley.com.au/asxdata/20100324/pdf/01049554.pdf

"Teva advised ANP that after performing certain steps in the development process, ATL1102 was determined to no longer be in line with Teva’s preferred product profile. ANP understands that business considerations or factors contributing to Teva’s decision include issues with one of the long-term toxicological studies that may require repeat of the study, lengthening the development time and time to market of the drug in light of the competitive landscape. "

From Taylor Collison Report Dated 27-Oct 2020
"ANP originally investigated ATL1102 as a treatment for multiple sclerosis (MS). ANP showed in a Phase II trial completed in 2008 that ATL1102 was effective in reducing the development of new lesions in MS patients.1 The efficacy was comparable to that of the marketed MS drug Tysabri, which targets the same VLA-4 pathway but via a different mechanism. ANP out-licenced ATL1102 to Teva in February 2008, but Teva returned the rights in March 2010, in part due to the need to conduct additional animal toxicology studies before progressing to the next stage of clinical development. ANP completed the additional animal safety studies but has not yet been able to attract another partner to fund further development of ATL1102 in MS. However, the company continues to explore opportunities to develop ATL1102 in this indication. "


Hope the above is clear.